Tandem Diabetes Care (TNDM) Projected to Post Quarterly Earnings on Wednesday

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) is expected to release its Q1 2025 earnings data after the market closes on Wednesday, April 30th. Analysts expect the company to announce earnings of ($0.60) per share and revenue of $220.19 million for the quarter.

Tandem Diabetes Care Trading Up 2.2 %

Shares of TNDM stock traded up $0.39 during trading hours on Friday, hitting $18.06. 1,156,715 shares of the company were exchanged, compared to its average volume of 1,502,017. The firm has a market cap of $1.20 billion, a PE ratio of -9.36 and a beta of 1.52. The firm has a fifty day moving average of $20.46 and a 200 day moving average of $29.44. Tandem Diabetes Care has a 1 year low of $15.75 and a 1 year high of $53.69. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29.

Insider Transactions at Tandem Diabetes Care

In related news, COO Jean-Claude Kyrillos acquired 10,538 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The shares were bought at an average cost of $18.12 per share, for a total transaction of $190,948.56. Following the purchase, the chief operating officer now owns 10,538 shares in the company, valued at $190,948.56. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 2.20% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on TNDM. Canaccord Genuity Group restated a "buy" rating and set a $63.00 price objective on shares of Tandem Diabetes Care in a research note on Wednesday, February 26th. Barclays dropped their price target on shares of Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. Mizuho started coverage on Tandem Diabetes Care in a research note on Thursday, April 10th. They set a "neutral" rating and a $20.00 target price for the company. Citigroup downgraded Tandem Diabetes Care from a "buy" rating to a "neutral" rating and cut their price objective for the company from $35.00 to $24.00 in a research report on Tuesday, March 4th. Finally, Wells Fargo & Company reaffirmed an "equal weight" rating and set a $22.00 target price (down from $38.00) on shares of Tandem Diabetes Care in a research report on Monday, March 3rd. Eight investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Tandem Diabetes Care has an average rating of "Moderate Buy" and a consensus target price of $43.88.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.